Glycine and D-Cycloserine in Schizophrenia
Launched by MASSACHUSETTS GENERAL HOSPITAL · Nov 2, 1999
Trial Information
Current as of May 11, 2025
Withdrawn
Keywords
ClinConnect Summary
To determine if glycine produces improvement in negative symptoms and D-cycloserine produces worsening in symptoms compared to placebo, patients will undergo a double blind study of d-cycloserine and glycine treatment added to clozapine.
Clozapine is more effective for negative symptoms of schizophrenia than conventional neuroleptics, but the neurochemical actions contributing to this superior clinical efficacy remain unclear. Recent evidence points to a role for glutamatergic dysregulation in schizophrenia, as well as important differences between conventional agents and clozapine in effe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Schizophrenia
- • Score of 27 or greater on the Scale for the Assessment of Negative Symptoms (SANS)
- • Treatment with stable dose of clozapine for at least 4 weeks
- • Between 18 and 65 years old
- Exclusion Criteria:
- • No other antipsychotic medications in oral for for at least 3 months or in depot form for 6 months
- • Current major depressive episode
- • Current substance abuse diagnosis
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Donald Goff, MD
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials